Clinical trials
Myelofibrosis (MF) clinical trials
Below are recruiting myelofibrosis (mf) clinical trials, each written for real people, not researchers. We’re tracking 25 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07357727RecruitingPhase 3
Study of Pelabresib and Ruxolitinib for Myelofibrosis
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
New Haven, ConnecticutAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT06479135RecruitingPhase 3
Study of new drug added to ruxolitinib for myelofibrosis
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Birmingham, AlabamaAges 18 years+ - NCT06770842RecruitingPhase 2
Study of two drugs for myelofibrosis with prior treatment
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
Hong KongAges 18 years+ - NCT06327100RecruitingPhase 1/Phase 2
Tasquinimod for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
Houston, TexasAges 18 years+ - NCT07128381RecruitingPhase 1/Phase 2
Axatilimab plus Ruxolitinib for Myelofibrosis and CMML
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
Houston, TexasAges 18 years+ - NCT06887803RecruitingPhase 1/Phase 2
Roginolisib plus ruxolitinib for myelofibrosis not helped by JAK inhibitors
This trial tests a new combination of two drugs, roginolisib and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough with ruxolitinib alone. It aims to see if adding roginolisib can improve symptoms and spleen size.
Florence, FlorenceAges 18 years+ - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Tampa, FloridaAges 18 years+ - NCT06343805RecruitingPhase 1
Study of LY5830966 for myelofibrosis after JAK inhibitor treatment
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT05280509RecruitingPhase 1/Phase 2
Test TL-895 plus ruxolitinib for myelofibrosis
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Birmingham, AlabamaAges 18 years+ - NCT06122831RecruitingPhase 1/Phase 2
TQ05105 and TQB3617 for myelofibrosis
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
Guangzhou, GuangdongAges 18 years+ - NCT07394153RecruitingPhase 2
Testing pacritinib for myelofibrosis patients with low platelets
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
Barcelona, BarcelonaAges 18 years+ - NCT07469891RecruitingPhase 1
Study of a new drug for myelofibrosis and polycythemia vera
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06414681RecruitingEarly Phase 1
Tagraxofusp and pacritinib for myelofibrosis after JAK inhibitor
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
Fairway, KansasAges 18 years+ - NCT07863466Recruiting
Tracking outcomes for chronic blood cancers
This study follows people with certain chronic blood cancers to understand how the diseases progress and how treatments affect outcomes over time. It may help improve care for future patients.
MilanAges 16 years+ - NCT07802405RecruitingPhase 1
Testing a new drug alone or with ruxolitinib for myelofibrosis
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
Zhengzhou, HenanAges 3 weeks+ - NCT07774455Recruiting
Pacritinib in real-world settings for myelofibrosis
This study looks at how well pacritinib works in everyday medical practice for people with myelofibrosis, a type of bone marrow disorder. It helps us understand the benefits and risks of this treatment for patients like you.
New Haven, ConnecticutAges 18 years+ - NCT07443306RecruitingPhase 2
Testing Flonoltinib for myelofibrosis after JAK inhibitor failure
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
Chengdu, SichuanAges 18–80 - NCT07419178Recruiting
New scan test for scarring in blood cancers
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
Parma, ItalyAges 18 years+ - NCT07317700RecruitingPhase 3
Study of a new pill for high-risk myelofibrosis
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
Chengdu, SichuanAges 18–80 - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Sacramento, CaliforniaAges 18–85 - NCT06541249RecruitingPhase 2
Adding methotrexate for blood cancers not controlled by current therapy
This trial is testing whether adding a low dose of methotrexate (a medicine often used for arthritis) can help people with certain blood cancers (myelofibrosis, polycythemia vera, or essential thrombocythemia) whose current treatments are not controlling their symptoms or blood counts well enough.
New York, New YorkAges 18 years+ - NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Gilbert, ArizonaAges 18 years+
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myelofibrosis (mf)?
- Yes. Clin2 currently lists 25 recruiting myelofibrosis (mf) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myelofibrosis (mf) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myelofibrosis (mf) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.